SWOG clinical trial number
CTSU/A082304/S2402

Perioperative Versus Adjuvant Systemic Therapy In Patients with Resectable Non-Small Cell Lung Cancer - PROSPECT LUNG, CTIU2317

Open
Abbreviated Title
PROSPECT LUNG
Status Notes
Effective 12/29/25, A082002/S2402 will be suspended to new patient enrollment for phase II analysis due to accrual completion.

CTSU/A082304/S2402 has been endorsed and activated by SWOG, effective 12/11/2025. CTSU/A082304/S2402 was activated by Alliance, effective 12/11/2024.
Activated
12/11/2024

Research committees

Lung Cancer

Treatment

Surgery

Publication Information Expand/Collapse

2025

Comparing impact of treatment before or after surgery in patients with stage II-IIIb resectable non-small cell lung cancer (NSCLC; Alliance A082304-SWOG S2402).

R Aljumaily;S Manrekar;Y Zhao;L Martin;D Kozono;S Hillman;A Chiang;R Osarogiagbon;T Stinchcombe;J Gray;D Morgensztern ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), poster; Abstract # TPS8113 Poster Bd # 234a

Other Clinical Trials

SWOG Clinical Trial Number
S2409

PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Research Committee(s)
Lung Cancer
Activated
09/08/2025
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA5231

A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Research Committee(s)
Lung Cancer
Activated
06/13/2025
Open
Phase
SWOG Clinical Trial Number
S2414

INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)
Research Committee(s)
Lung Cancer
Symptom Management and Survivorship
Activated
03/14/2025
Accrual
2%
Open
Phase